Recro Pharma (NASDAQ:REPH) will post its quarterly earnings results before the market opens on Thursday, August 8th. Analysts expect Recro Pharma to post earnings of ($0.35) per share for the quarter. Recro Pharma has set its FY 2019 guidance at EPS.
Recro Pharma (NASDAQ:REPH) last announced its earnings results on Friday, May 10th. The specialty pharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.69. The firm had revenue of $25.07 million during the quarter, compared to analysts’ expectations of $20.51 million. Recro Pharma had a negative return on equity of 472.52% and a negative net margin of 83.56%. On average, analysts expect Recro Pharma to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Shares of NASDAQ REPH traded down $0.30 during trading hours on Friday, reaching $9.29. The stock had a trading volume of 28,867 shares, compared to its average volume of 138,686. The stock has a market capitalization of $217.15 million, a price-to-earnings ratio of -3.73 and a beta of -0.17. Recro Pharma has a fifty-two week low of $5.23 and a fifty-two week high of $10.69. The business’s 50-day simple moving average is $9.92.
A number of brokerages recently issued reports on REPH. Zacks Investment Research cut Recro Pharma from a “buy” rating to a “hold” rating in a research report on Friday. Oppenheimer upped their target price on Recro Pharma from $9.00 to $15.00 and gave the company an “outperform” rating in a research report on Thursday, April 4th. Finally, ValuEngine raised Recro Pharma from a “hold” rating to a “buy” rating in a research report on Friday, May 24th. Two equities research analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company presently has an average rating of “Buy” and a consensus target price of $11.30.
In other Recro Pharma news, CEO Geraldine Henwood sold 144,806 shares of the company’s stock in a transaction that occurred on Monday, May 13th. The stock was sold at an average price of $8.89, for a total transaction of $1,287,325.34. Following the completion of the sale, the chief executive officer now directly owns 342,947 shares of the company’s stock, valued at approximately $3,048,798.83. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Arnaud Ajdler acquired 40,000 shares of Recro Pharma stock in a transaction on Friday, May 17th. The shares were bought at an average cost of $9.00 per share, with a total value of $360,000.00. The disclosure for this purchase can be found here. 20.10% of the stock is owned by corporate insiders.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
See Also: Trading on Margin
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.